Consequently, activating the EGFR/AKT signaling pathway while inhibiting MAPK activity can effectively mitigate inflammation and enhance the integrity of the skin barrier, representing a promising strategy for the treatment of HFS. Here, AKT1 is linked to Hand-foot syndrome.